Pharmacologic rationale for intravesicalN-Trifluoroacetyladriamycin-14-valerate (AD 32): a preclinical study

[1]  G. Eisenbrand,et al.  Androgen-linked alkylating agents: biological activity in methylnitrosourea-induced rat mammary carcinoma , 2005, Journal of Cancer Research and Clinical Oncology.

[2]  N. Gebbia,et al.  Permeability of the bladder mucosa to thiotepa, adriamycin, and daunomycin in men and rabbits , 1976, Urological Research.

[3]  R. Seshadri,et al.  Comparative uptake and retention of adriamycin andN-benzyladriamycin-14-valerate in human CEM leukemic lymphocyte cell cultures , 2004, Cancer Chemotherapy and Pharmacology.

[4]  R. Hunter,et al.  Effects of N-trifluoroacetyladriamycin-14-valerate (AD-32) on human bladder tumor cell lines , 2004, Cancer Chemotherapy and Pharmacology.

[5]  A. Iliadis,et al.  Time dependency of adriamycin and adriamycinol kinetics , 2004, Cancer Chemotherapy and Pharmacology.

[6]  W. Hoffman.  Introduction and Overview of Intravesical Therapy for Superficial Bladder Cancer , 1988 .

[7]  V. Laudone,et al.  An overview of intravesical therapy for superficial bladder tumors. , 1987, The Journal of urology.

[8]  F. Torti,et al.  The biology and treatment of superficial bladder cancer. , 1984, Journal of Clinical Oncology.

[9]  J. Richie,et al.  Intravesical doxorubicin for prophylaxis in the management of recurrent superficial bladder carcinoma. , 1984, The Journal of urology.

[10]  M. Sack,et al.  Phase II Evaluation of N-Trifluoroacetyladriamycin-14-Valerate (AD 32) , 1982 .

[11]  I. Strøyer,et al.  Absorption of doxorubicin hydrochloride during bladder washings in treatment of noninvasive bladder tumors. , 1981, Urology.

[12]  V. Devita,et al.  Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute. , 1981, European journal of cancer.

[13]  I. Henderson,et al.  Preclinical rationale and phase I clinical trial of the adriamycin analog, AD 32. , 1981, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[14]  S. Crooke,et al.  Phase I-II study of mitomycin C topical therapy for low-grade, low stage transitional cell carcinoma of the bladder: an interim report. , 1980, Cancer treatment reports.

[15]  A. Renwick,et al.  The absorption of saccharin from the rat urinary bladder , 1979, The Journal of pharmacy and pharmacology.

[16]  M. Israel,et al.  N-trifluoroacetyladriamycin-14-valerate: additional mouse antitumor and toxicity studies. , 1978, Cancer treatment reports.

[17]  A. Mantovani,et al.  Comparative antineoplastic activity of adriamycin and N-trifluoroacetyladriamycin-14-valerate. , 1978, Cancer treatment reports.

[18]  E. Modest,et al.  Differences in cellular uptake and cytofluorescence of adriamycin and N-trifluoroacetyladriamycin-14-valerate. , 1976, Cancer research.

[19]  E. Modest,et al.  N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin. , 1975, Cancer research.